ICLEa19-0021
CARs Targeting Solid Tumors

DEVELOPMENT OF TCR-LIKE SCFV ZG CAR THAT SPECIFICALLY RECOGNIZES MAGE-A4230-239/HLA-A*02:01 COMPLEX

Akahori¹, Y. Kato², Y. Miyahara³, C. Amaike³, L. Wang³, K. Takuma⁴, H. Fujiwara³, H. Miwa⁵, H. Ikeda⁶, H. Shiku^3
1Mie University, Department of Immuno-Gene Therapy, Tsu city, Japan
²Mie Univercity, Department of Immuno-Gene Therapy, Tsu, Japan
³Mie University, Department of Immuno-Gene Therapy, Tsu, Japan
⁴Mie University, Department of Immunology, Tsu, Japan
⁵Mie University, Immuno-Gene Therapy, Tsu, Japan
⁶Nagasaki University, Department of Oncology, Nagasaki, Japan 

————————————–

ICLEa19-0033
CARs Targeting Solid Tumors

TARGETING MYELOID-DERIVED SUPPRESSOR CELLS AND IN SITU VACCINATION TO ENHANCE EFFICACY OF CAR T CELLS IN SOLID TUMORS

Conde-Gallastegi¹, J. Suarez¹, E. Elizalde¹, E. Vercher¹, U. Mancheño¹, N. Casares¹, T. Lozano¹, J.J. Lasarte¹, S. Hervás-Stubbs^1
1CIMA Universidad de Navarra, Immunology and immunotherapy program, Pamplona, Spain 

————————————–

ICLEa19-0027
CARs Targeting Solid Tumors

SUPPRESSION OF T CELLS THROUGH IN VITRO POLARISED MYELOID CELLS AS A BASIS FOR HIGH THROUGHPUT DRUG SCREENINGS TO IMPROVE IMMUNOTHERAPY OF SOLID CANCERS

Frosch¹, L. Gargiulo¹, C. Hanif Muflihah¹, J. Anderson^1
1UCL Institute of Child Health, Developmental Biology and Cancer, London, United Kingdom 

————————————–

 ICLEa19-0020
CARs Targeting Solid Tumors

CAR-BASED IMMUNOTHERAPY OF EGFR-POSITIVE SOLID TUMOURS USING CYTOKINE-ACTIVATED PERIPHERAL BLOOD KILLER CELLS

Gavriliuc^1,2, R. Zogorean¹, F. Bojin^1,2, V. Paunescu^1,2
1“Pius Brinzeu” Clinical Emergency County Hospital Timisoara, OncoGen Center for Gene and Cellular Therapies in the Treatment of Cancer, Timisoara, Romania
²“Victor Babes” University of Medicine and Pharmacy Timisoara, Immunology, Timisoara, Romania 

————————————–

ICLEa19-0038
CARs Targeting Solid Tumors

POTENTIAL CANCER STEM CELL TARGETING CHIMERIC ANTIGEN RECEPTOR GENERATION WITH ANTIBODY VARIABLE REGION GENES IDENTIFIED BY IMMUNOGLOBULIN PROFILE ANALYSIS IN PATIENTS WITH MALIGNANT MELANOMA

Kotlan¹, S. Horvath², K. Eles², K. Czirbesz³, G. Naszados⁴, J. Olasz⁵, E. Farkas⁶, M. Ujhelyi⁶, A. Szollar⁶, A. Savolt⁶, O. Csuka⁵, M. Godeny⁴, M. Kasler⁷, G. Liszkay^3
1National Institute of Oncology, Molecular Immunology and Toxicology, Budapest, Hungary
²National Institute of Oncology, Center of Surgical and Molecular Pathology, Budapest, Hungary
³National Institute of Oncology, Department of Oncodermatology, Budapest, Hungary
⁴National Institute of Oncology, Center of Image Analysis and Radiological Diagnostics, Budapest, Hungary
⁵National Institute of Oncology, Department of Pathogenetics, Budapest, Hungary
⁶National Institute of Oncology, Center of Oncosurgery, Budapest, Hungary
⁷Ministry of Human Capacities, n, Budapest, Hungary 

————————————–

ICLEa19-0049
CARs Targeting Solid Tumors

OPTIMIZING CRISPR-CAS9 MEDIATED KNOCK-IN STRATEGY TO CREATE AN INDUCIBLE GENE EXPRESSION SYSTEM IN PRIMARY HUMAN T CELLS

Odé¹, C.T. Petersen¹, G. Krenciute^1
1St. Jude Children’s Research Hospital, Bone Marrow Transplantation and Cellular Therapy, Memphis, USA

————————————–

ICLEa19-0017
CARs Targeting Solid Tumors

TRASTUZUMAB DERIVED HER2-SPECIFIC CAR FOR TRASTUZUMAB-RESISTANT BREAST CANCER: CAR T-CELLS SUCCESSFULLY ENGAGE TARGET EPITOPES THAT ARE NOT ACCESSIBLE TO ANTIBODIES

Szoor¹, B. Zsebik¹, V. Szabo¹, H. Abken², G. Vereb^1
1University of Debrecen, Department of Biophysics and Cell Biology, Debrecen, Hungary
²Regensburg Center for Interventional Immunology, Chair for Genetic Immunotherapy, Regensburg, Germany 

————————————–

 ICLEa19-0050
CARs Targeting Solid Tumors

IMPROVING CEA-TARGETED CAR-T CELL THERAPY FOR SOLID TUMOURS

Zheng¹, G. Kueberuwa¹, E. Cheadle¹, A. Armstrong^2
1University of Manchester, Divison of Cancer Sciences, Manchester, United Kingdom
²The Christie NHS Foundation Trust, Department of Medical Oncology, Manchester, United Kingdom 

————————————–

 ICLEa19-0005
Fighting Infections and Autoimmune Diseases

ENGINEERING CELL-DERIVED NANOSCALE EXOSOMES FOR ANTI-INFLAMMATION AND IMMUNOTHERAPY

Levy¹, M. Do¹, A. Brown¹, B. Lu^1
1Santa Clara University, Department of Bioengineering, Santa Clara, USA

————————————–

ICLEa19-0019
Fighting Infections and Autoimmune Diseases

DEVELOPING A CRISPR-CAS9 TOOL TO INACTIVATE THE GLUCOCORTICOID RECEPTOR AND BROADEN THE APPLICABILITY OF ANTIGEN-SPECIFIC T-CELL IMMUNOTHERAPY

Alvanou¹, C. Pantazi², K. Koukoulias², N. Psatha³, G. Tsiolas⁴, I. Vallianou⁵, M. Yiangou⁶, A. Spyridonidis⁷, K. Stamatopoulos⁴, A. Anagnostopoulos⁵, A. Makris⁴, E. Yannaki⁵, A. Papadopoulou^5
1G.Papanikolaou Hospital/University General Hospital of Patras, Gene and Cell Therapy Unit-Haematology Department, Thessaloniki, Greece
²G.Papanikolaou Hospital/Aristotle University of Thessaloniki, Gene and Cell Therapy Unit-Haematology Department/Department of Genetics- Development and Molecular Biology, Thessaloniki, Greece
³Altius Institute for Biomedical Sciences, Altius Institute for Biomedical Sciences, Seattle, USA
⁴Institute of Applied Biosciences INAB, Centre for Research and Technology Hellas CERTH, Thessaloniki, Greece
⁵G.Papanikolaou Hospital, Gene and Cell Therapy Unit-Haematology Department, Thessaloniki, Greece
⁶Aristotle University of Thessaloniki, Department of Genetics- Development and Molecular Biology, Thessaloniki, Greece
⁷University General Hospital of Patras, Department of Haematology, Patras, Greece 

————————————–

 ICLEa19-0031
Fighting Infections and Autoimmune Diseases

DEEP-PRIMED IL-15 SUPERAGONIST IMPROVES ANTIVIRAL EFFICACY OF HIV-SPECIFIC CD8+ T-CELLS IN A HUMANIZED MOUSE MODEL

Mccann^1,2, E. Zale², A. Ward^3,4, T. Dilling^1,5, A. Danesh¹, E. Stevenson¹, T. Mota¹, T. Andresen⁶, D. Jones⁶, D. Irvine⁷, R.B. Jones^1,2,3
1Weill Cornell Medical College, Medicine, New York NY, USA
²Weill Cornell Graduate School of Medical Sciences, Immunology and Microbial Pathogenesis, New York NY, USA
³The George Washington University, Microbiology Immunology & Tropical Medicine, Washington DC, USA
⁴The George Washington University Milken Institute School of Public Health, Epidemiology, Washington DC, USA
⁵The Graduate Center – City University of New York, PhD Program in Chemistry, New York NY, USA
⁶Torque Therapeutics, Bioengineering, Cambridge MA, USA
⁷Massachusetts Institute of Technology, Koch Institute for Integrative Cancer Research, Cambridge MA, USA

————————————–

ICLEa19-0043
Fighting Infections and Autoimmune Diseases

CHARACTERIZATION OF MHC CLASS II-RESTRICTED T-CELL RECEPTORS FOR T-CELL THERAPY OF HBV INFECTION

Schreiber¹, M. Honz¹, M. Schiemann², A. Sette³, C. Zielinski¹, U. Protzer¹, K. Wisskirchen^1
1Technical University of Munich / Helmholtz Zentrum Munich, Institute of Virology, Munich, Germany
²Technical University of Munich, Institute for Medical Microbiology- Immunology and Hygiene, Munich, Germany
³La Jolla Institute for Immunology, Center for Infectious Disease, La Jolla, USA 

————————————–

 ICLEa19-0046
Fighting Infections and Autoimmune Diseases

VACCINE ELICITATION OF HIV BROADLY NEUTRALIZING ANTIBODIES FROM ENGINEERED B CELLS

Voss¹, D. Huang¹, J. Tran¹, J. Abadajos¹, A. Olson¹, K. Saye¹, T. Blane¹, R. Fuller¹, L. Couvrette¹, M. Tenuta¹, W. Li¹, T. Schiffner¹, E. Landais², A. Gonzalez-Martin³, D. Sok², D. Burton¹, W. Schief¹, D. Nemazee^1
1Scripps Research, Immunology and Microbiology, La Jolla, USA
²Scripps Research, IAVI Neutralizing Antibody Center, La Jolla, USA
³Universidad Autonoma de Madrid, Department of Biochemistry, Madrid, Spain

————————————–

ICLEi19-0004
Genome Editing for Allogeneic ACT

The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy

S. Raitano¹, A. Michaux², S. Bornschein², J. Bolsée³, S. Lenger⁴, H. Machado⁵, P. Sotiropoulou², D. Gilham^2
1Celyad, R&D, Mont-Saint-Guibert, Belgium
²Celyad, Research and Development, Mont Saint Guibert, Belgium
³Celyad, Research and Development, Mont Saint Guibrt, Belgium
⁴Horizon discovery, Research and development, Lafayette, USA
⁵Horizon Discovery, Research and Develompment, Lafayette, USA

————————————–

ICLEa19-0044
Hematological Malignancies

CRISPR-CAS9 MEDIATED GENERATION OF CORD BLOOD TCRΑΒ-/- CD8+ T CELLS EXPRESSING RECOMBINANT WT1-TCR TO DECREASE RELAPSE IN ACUTE MYELOID LEUKEMIA PEDIATRIC PATIENTS

Lo Presti¹, E. Dunnebach¹, M. Plantinga¹, K. Jurgen¹, S. Nierkens¹, J.J. Boelens², N. van Til^1
1UMC Utrecht, LTI-Applied, Utrecht, The Netherlands
²MSK-Cancer Center, Pediatrics, New York, USA 

————————————– 

ICLEa19-0030
Hematological Malignancies

REPROGRAMMED CAR T CELLS MAINTAIN METABOLIC POTENTIAL DURING RAPID EXPANSION AND SHOW INCREASED ANTI-TUMOR REACTIVITY

Mølgaard¹, Ö. Met¹, I.M. Svane^1
1Center for Cancer Immune Therapy, Department of Hematology- Herlev Hospital, Herlev, Denmark

————————————–

ICLEa19-0035
Hematological Malignancies

HEMATOPOIETIC MINOR HISTOCOMPATIBILITY ANTIGEN-SPECIFIC CD8+ T CELLS FOR ANTI-RELAPSE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Pilunov¹, D. Romaniuk¹, S. Sheetikov¹, A. Khmelevskaya¹, A. Shmelev¹, N. Bykova¹, A. Shomuradova¹, D. Kiryukhin¹, D. Dianov¹, G. Efimov^1
1National Research Center for Hematology, Laboratory of Transplantation Immunology, Moscow, Russia 

————————————–

ICLEa19-0041
New Horizons in Lympocyte Engineering

IN VIVO THYMOCYTE ENGINEERING

Gritsenko¹, M. Fried¹, C. Pundak-Mintz¹, Y. Zilberstein², I. Dotan¹, A. Zoaby¹, A. Globerson Levin³, A. Barzel^1
1Tel Aviv University, Biochemistry and Molecular Biology, Tel aviv, Israel
²Tel Aviv University, Sackler Cellular and Molecular Imaging Center, Tel aviv, Israel
³Tel Aviv Sourasky Medical Center TASMC, Immunology research center, Tel aviv, Israel

————————————–

ICLEa19-0048
New Horizons in Lympocyte Engineering

ADVANCING CAR T CELL THERAPY UTILIZING IN SITU TRANSDUCTION

Horn¹, A. Najjar², A. Globerson Levin¹, T. Waks¹, Z. Eshhar^1
1The Tel Aviv Sourasky Medical Center, Immunology lab, Tel Aviv, Israel
²The University of Texas M.D. Anderson Cancer Center, Department of Pediatrics, Houston- Texas, USA

————————————– 

ICLEa19-0039
New Horizons in Lympocyte Engineering

ENGINEERING B CELLS FOR A REGULATED, IMMUNODOMINANT AND EVOLVING TREATMENT FOR HIV INFECTIONS

Nahmad¹, T. Akriv¹, D. Nataf¹, M. Fried¹, I. Dotan¹, Y. Wine², I. Benhar², A. Barzel^1
1Tel Aviv University, Biochemistry and Molecular Biology, Tel Aviv, Israel
²Tel Aviv University, Department Molecular Microbiology and Biotechnology, Tel Aviv, Israel

————————————–

ICLEa19-0015
New Horizons in Lympocyte Engineering

TOWARDS SAFE AND EFFICIENT DELIVERY OF MRNA AND CRISPR-CAS9 COMPLEXES IN T CELLS BY VAPOR NANOBUBBLE PHOTOPORATION

Raes¹, S. Stremersch¹, J. Fraire¹, T. Brans¹, G. Goetgeluk², J. Van Hoeck¹, R. Xiong¹, B. Vandekerckhove², S. De Smedt C.¹, K. Raemdonck¹, K. Braeckmans^1
1Ghent University, Department of Pharmaceutics, Ghent, Belgium
²Ghent University, Department of Clinical Chemistry- Microbiology and Immunology, Ghent, Belgium

————————————– 
ICLEa19-0023
Other

SYNTHETIC SURFACES FOR ENHANCEMENT OF T-CELL THERAPIES

Adutler-Lieber¹, N. Friedman¹, B. Geiger^2
1Weizmann Institute of Science, Immunology, Rehovot, Israel
²Weizmann Institute of Science, Molecular Cell Biology, Rehovot, Israel 

————————————– 
ICLEi19-0008
Other

RECEPTORS PROVIDING TUMOUR ANTIGEN RESTRICTED COSTIMULATION ENHANCE T-CELL ACTIVITY FOR ADOPTIVE T-CELL THERAPY

Sykorova¹, M. Kalaitsidou¹, M. Le Brocq¹, A. Patel¹, T. Katopodi¹, R. Hawkins¹, G. Kueberuwa¹, J. Bridgeman^1
1Immetacyte Ltd., Research & Development, Manchester, United Kingdom

————————————– 
ICLEi19-0010
Other

NANOSTRAW-MEDIATED DELIVERY ENABLES FAST AND EFFICIENT DELIVERY OF MOLECULAR CARGO TO HARD-TO-TRANSFECT MAMMALIAN CELLS IN A NON-PERTURBATIVE FASHION WHILE MAINTAINING HIGH VIABILITY

Johnson¹, S. Leal-Ortiz¹, M. Hjort¹, H. Vossfeldt¹, R. Swoboda¹, S. Boyatzis^1
1Navan Inc, Navan Inc, South San Francisco, USA

————————————– 

 ICLEa19-0051
Other

THE ROLE OF THE EXTRACELLULAR CD28 DOMAIN IN CAR T CELLS: MONOMERISATION AND TRUNCATION IMPACT THE ACTIVATION OF CD28 CAR T CELLS

Kilgallon¹, R. Hawkins¹, E. Cheadle¹, J. Bridgeman¹, A. Armstrong¹, D. Gilham¹, A. Schutt¹, M. Kalaitsidou¹, G. Kueberuwa^1
1University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom

————————————– 
ICLEa19-0009
Other

MELANOMA-INFILTRATING DENDRITIC CELLS ARE REQUIRED FOR LICENSING THE CYTOTOXIC ACTIVITY OF CD8+ T CELLS IN SITU

Santana-Magal¹, L. Farhat-Younis¹, D. Rasoulouniriana¹, A. Gutwillig¹, L. Tal¹, P. Rider¹, Y. Carmi^1
1Tel Aviv University, Department of Pathology- Sackler School of Medicine, Tel Aviv, Israel

————————————– 

ICLEa19-0037
TCR Targeting Solid Tumors

IDENTIFICATION OF A T CELL RECEPTOR SPECIFIC FOR GLYPICAN 3 FOR ADOPTIVE IMMUNOTHERAPY

Hervas-Stubbs¹, J. Gonzalez-Vaz¹, U. Mancheno¹, E. Elizalde¹, I. Tamayo¹, P. Sarobe^1
1Center for Applied Medical Research CIMA- University of Navarra, Immunology and Immunotherapy, Pamplona, Spain 

————————————– 

 ICLEa19-0042
TCR Targeting Solid Tumors

A NOVEL TCR CLONING SYSTEM OF PEPTIDE-SPECIFIC T CELLS USING IMMUNOSPOT ARRAY ASSAY ON A CHIP (T-ISAAC) TECHNOLOGY

E. Kobayashi¹, T. Ozawa¹, H. Hamana¹, K. Shitaoka¹, A. Muraguchi¹, H. Kishi^1
1University of Toyama, Department of Immunology, Toyama-shi, Japan 

ICLEa19-0013
CARs Targeting Solid Tumors

A NOVEL UNIVERSAL CAR T CELLS IMMUNOTHERAPY FOR THE TREATMENT OF SOLID TUMORS

Farhat-Younis¹, D. Rasoulouniriana¹, N. Santana-Magal¹, A. Gutwillig¹, L. Tal¹, P. Rider¹, Y. carmi ^1
1Sackler School of Medicine- Tel Aviv University, Pathology, Tel Aviv, Israel

———————————————–

ICLEa19-0036
CARs Targeting Solid Tumors

REDIRECTION OF UNICAR T CELL AGAINST EGFR+ TUMOR CELLS BY USING DIFFERENT αEGFR TARGETING MODULE FORMATS

Jureczek^1,2, A. Feldmann³, S. Albert³, R. Bergmann³, N. Berndt^1,3, C. Arndt³, S. Koristka³, M. Bachmann^1,2,3,4
1German Cancer Consortium DKTK- partner site Dresden, German Cancer Research Center DKFZ- Heidelberg- Germany, Dresden, Germany
²University Cancer Center UCC, Tumor Immunology- University Hospital Carl Gustav Carus- TU Dresden, Dresden, Germany
³Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf HZDR, Dresden, Germany
⁴National Center for Tumor Diseases NCT- partner site Dresden, University Hospital Carl Gustav Carus- TU Dresden, Dresden, Germany

———————————————–

ICLEa19-0024
CARs Targeting Solid Tumors

A THERANOSTIC DRUG FOR PROSTATE CANCER CAR T CELL IMMUNOTHERAPY AND PET IMAGING

 Arndt¹, S. Koristka¹, N. Berndt¹, R. Bergmann¹, L. Loureiro¹, J. Kotzerke², M. Bachmann¹, A. Feldmann^1
1Helmholtz-Zentrum Dresden-Rossendorf HZDR, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany
²University Hospital ‘Carl Gustav Carus’ TU Dresden, Department of Nuclear Medicine, Dresden, Germany

———————————————–

ICLEa19-0012
CARs Targeting Solid Tumors

A NOVEL SUBSET OF CD4+ T CELL EXPRESSING THE HIGH AFFINITY Fcγ RECEPTOR LINKS ANTIBODY AND T CELL IMMUNITY

Rasoulouniriana¹, N. Santana-Magal¹, A. Gutwillig¹, Y. Wine², C. Saperia¹, L. Farhat¹, L. Tal¹, H. Gutman¹, A. Tsivian L.³, R. Brenner⁴, E. Abu Bandora¹, N. Reticker-Flynn⁵, P. Rider¹, Y. Carmi^1
1Tel Aviv University, Pathology, Tel Aviv, Israel
²Tel Aviv University, Molecular Microbiology and Biotechnology, Tel Aviv, Israel
³The Edith Wolfson Medical Center, Department of Urologic Surgery, Holon, Israel
⁴The Edith Wolfson Medical Center, Gastrointestinal Oncology Clinic, Holon, Israel
⁵Massachusetts Institute of Technology, Pathology, Massachusetts, United States Minor Outlying Island

———————————————–
 
ICLEa19-0045
Fighting Infections and Autoimmune Diseases

CD4+CD25+CD127HI CELLS CORRELATE WITH LENGTH OF REMISSION IN TYPE 1 DIABETES: VALIDATED IN A MULTI-SITE STUDY

Narsale¹, R. Moya¹, H. Robertson¹, D. Payne¹, T.T. Lu², R. Geoffery³, K. Buchanan⁴, M. Harris⁵, A.S. Bergot⁵, R. Thomas⁵, M. Hessner⁶, M. Battaglia⁷, E. Serti⁸, J. Davies^1
1San Diego Biomedical Research Institute, Davies Lab, San Diego, USA
²Immune Tolerance Network, Immune Tolerance Network, Washington DC, USA
³The Medical College of Wisconson, Dept of Pediatrics, Milwaukee, USA
⁴University of Queensland, Diamantina Institute-, Woolloongabba, Australia
⁵University of Queensland, Diamantina Institute, Woolloongabba, Australia
⁶The Medical College of Wisconsin, Department of Pediatrics, Milwaukee, USA
⁷Diabetes Research Institute DRI, IRCCS San Raffaele Scientific Institute, Segrate, Italy
⁸Immune Tolerance Network, Biomarker and Discovery, Seattle, USA

———————————————–

 ICLEi19-0005
Fighting Infections and Autoimmune Diseases

IMPROVED CONTROL OF ACTIVATION AND EXPANSION OF TREGS FOR USE IN CELL THERAPY APPLICATIONS

I.C. Schrøder¹, K. Bernström¹, N. Lieske¹, D. Gjølberg¹, G. Økern¹, H. Zhang¹, T.H. Hereng¹, U. Rehn², Ø. Åmellem^3
1Thermo Fisher Scientific, Research and development- Cell Medicine, Oslo, Norway
²Thermo Fisher Scientific, Cell Culture and Cell Therapy, New York, USA
³Thermo Fisher Scientific, Cell Culture and Cell Therapy, Oslo, Norway

———————————————–

ICLEa19-0007
Hematological Malignancies

ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD NK CELLS ARE GOOD SOURCES FOR EFFECTIVE CAR THERAPY AGAINST CD19 POSITIVE LEUKEMIC CELLS

Herrera¹, S. Santos¹, M.A. Vesga¹, J. Anguita², I. Martin-Ruiz², T. Carrascosa³, M. Juan⁴, C. Eguizabal^1
1Osakidetza- Basque Center for Blood Transfusion and Human Tissues, Cell Therapy and Stem Cells Group, Galdakao- 48960- Spain, Spain
²CIC bioGUNE, Macrophage and Tick Vaccine Laboratory, Derio- Biscay, Spain
³Osakidetza-Hospital Galdakao-Usansolo, Servicio de Hematología, Galdakao, Spain
⁴Hospital  Clínic de Barcelona. Hospital Sant Joan de Déu. Institut d’Investigacions Biomèdiques August Pi i Sunyer Hospital. Universitat de Barcelona, Servei d´Immunologia, Barcelona, Spain

———————————————–

ICLEa19-0026
New Horizons in Lympocyte Engineering

GENETIC MODIFICATION OF CD8+ T CELLS TO EXPRESS EGFR: POTENTIAL APPLICATION FOR ADOPTIVE T CELL THERAPIES

Casares¹, J.J. Lasarte¹, T. Lozano¹, S. Chocarro¹, C. del Valle¹, M. Gorraiz¹, S. Hervas-Stubbs¹, P. Sarobe^1
1Center for Applied Medical Research CIMA, Immunology and Immunotherapy Program, Pamplona, Spain

———————————————–

ICLEa19-0008
New Horizons in Lympocyte Engineering

UNDERSTANDING THE EXPRESSION PROFILE OF NKG2D LIGANDS ON T CELLS: IMPLICATIONS FOR CAR T CELL THERAPY

Demoulin¹, E. Breman¹, S. Bornschein¹, M. Fontaine¹, P. Sotiropoulou A.¹, D. Gilham^1
1Celyad, Research and development, Mont-Saint-Guibert, Belgium

———————————————–

 ICLEa19-0006
New Horizons in Lympocyte Engineering

ESTABLISHING NOVEL RECEPTOR-TARGETED LENTIVIRAL VECTORS FOR T-LYMPHOCYTE-DIRECTED IN VIVO GENE DELIVERY

Frank¹, F.B. Thalheimer², W. Uckert³, J. Hartmann¹, C.J. Buchholz^1
1Paul-Ehrlich-Institut, Division of Medical Biotechnology, Langen, Germany
²Paul-Ehrlich-Institut, Molecular Biotechnology and Gene Therapy, Langen, Germany
³Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Molecular Cell Biology and Gene Therapy, Berlin, Germany

———————————————–

 ICLEa19-0032
New Horizons in Lympocyte Engineering

A LIPOCALIN-BASED ON-SWITCH FOR CONTROLLING CAR T CELLS WITH AN ORALLY AVAILABLE DRUG

Brey¹, M. Dobersberger¹, I. Schaffner², G. Mlynek³, D. Pühringer³, B. Salzer¹, K. Djinovic-Carugo³, C. Obinger⁴, W. Holter⁵, M. Traxlmayr⁴, M. Lehner^1
1Children’s Cancer Research Institute, Development of Cellular Therapeutics, Vienna, Austria
²BOKU-University of Natural Resources and Life Sciences, Core Facility for Biomolecular & Cellular Analysis, Vienna, Austria
³University of Vienna, Department for Structural and Computational Biology- Max F. Perutz Laboratories, Vienna, Austria
⁴BOKU-University of Natural Resources and Life Sciences, Department of Chemistry, Vienna, Austria
⁵Medical University of Vienna, St. Anna Kinderspital, Vienna, Austria 

———————————————–

ICLEa19-0047
New Horizons in Lympocyte Engineering

ENGINEERING T CELLS AND B CELLS FOR IMMUNOTHERAPY USING V(D)J RECOMBINATION

Nataf¹, I. Dotan¹, M. Horovitz-Fried¹, N. Gritsenko¹, C. Pundak-Mintz¹, A. Nahmad¹, A. Barzel^1
1Tel Aviv University, School of Neurobiology- Biochemistry & Biophysics, Tel Aviv, Israel

———————————————–

ICLEa19-0016
Non-Viral Vectors and Transposons

VAPOR NANOBUBBLE PHOTOPORATION AS A NEW, SAFE AND EFFICIENT TECHNIQUE FOR THE DELIVERY OF SMALL INTERFERING RNA TO LYMPHOCYTE CELLS

Van Hoeck¹, L. Wayteck¹, R. Xiong¹, K. Braeckmans¹, S.C. De Smedt¹, K. Raemdonck^1
1Ghent University, Faculty of Pharmaceutical Sciences, Ghent, Belgium

ICLEa19-0040
Other

DIRECT TRANSGENE EXPRESSION AND MAB PRODUCTION BY USING NEW GENERATION MINIMISED UCOES ON HUMAN IPS AND CHO CELLS

Anakok^1
1ATATURK UNIVERSITY, MOLECULAR BIOLOGY and GENETICS, Erzurum, Turkey

———————————————–

ICLEi19-0009
Other

RECOMBINANT GROWTH FACTOR RECEPTORS ENHANCE T-CELL PROLIFERATION AND ANTI-TUMOUR ACTIVITY IN A MODEL OF ADOPTIVE T-CELL THERAPY

Le Brocq¹, T. Katopodi¹, M. Sykorova¹, H. Crookes¹, N. Hurst², R. Hawkins¹, G. Kueberuwa¹, J. Bridgeman^1
1Immetacyte Ltd., Research & Development, Manchester, United Kingdom
²University of Leeds, Biological Sciences, Leeds, United Kingdom

———————————————–

ICLEa19-0018
Other

IMPLICATION OF TRPV1 IN TEMPERATURE AND PH-SENSING BY CANINE PBMC

Bujak¹, D. Kosmala¹, A. Nyc¹, I. Szopa¹, K. Majchrzak¹, P. Bednarczyk^2
1Warsaw University of Life Sciences – SGGW, Department of Physiological Sciences, Warsaw, Poland
²Warsaw University of Life Sciences – SGGW, Department of Biophysics, Warsaw, Poland

———————————————–

ICLEa19-0025
Other

Effector CD4+ T cells, rather than CD8+, increase the efficacy of antibody-driven tumor immunity

Gutwillig¹, D. Rasoulouniriana¹, N. Santana-Magal¹, L. Farhat¹, L. Tal¹, P. Rider¹, Y. carmi ^1
1Tel-Aviv University, pathology, Tel Aviv, Israel 

———————————————–

ICLEa19-0022
Other

PROGRAMMING OF CD4+ T LYMPHOCYTES TOWARD A TH17 PHENOTYPE – IN VITRO STUDY ON COMPANION DOG MODEL

Szopa¹, J. Bujak¹, M. Granica¹, K. Majchrzak^1
1Warsaw University of Life Sciences – Faculty of Veterinary Medicine, Department of Physiological Sciences, Warsaw, Poland 

———————————————–

 ICLEi19-0006
TCR Targeting Solid Tumors

GMP MANUFACTURING OF TCR-ENGINEERED T CELLS IN 5-6 DAYS

M. Kalra¹, Z. Coughlin¹, A. Alpert², L. Alten³, S. Bunk³, C. Wagner³, J. Fritsche⁴, O. Schoor⁴, D. Maurer³, T. Weinschenk⁴, K. Sieger⁵, A. Mohamed¹, S. Walter^6
1Immatics US Inc, Chemistry Manufacturing & Control, Houston, USA
²Immatics US Inc, Immunology, Houston, USA
³Immatics Biotechnologies GmbH, Immunology, Tuebingen, Germany
⁴Immatics Biotechnologies GmbH, Discovery, Tuebingen, Germany
⁵Immatics US Inc, Quality Control & Quality Assurance, Houston, USA
⁶Immatics US Inc, Sr Management, Houston, USA